ArticleInternational journal of surgery (London, England)2025
Development and validation of the NTAA prognostic model for BCLC stage B hepatocellular carcinoma undergoing transarterial chemoembolization: a retrospective multicenter cohort study.
Article in International journal of surgery (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Advancing risk stratification in intermediate-stage hepatocellular carcinoma undergoing transarterial chemoembolization: the promise of the NTAA model.Hepatobiliary surgery and nutrition · 2026Article
- Refining prognostication in intermediate-stage hepatocellular carcinoma after transarterial chemoembolization: promise and limitations of the proposed NTAA model.Hepatobiliary surgery and nutrition · 2026Article
- Transarterial chemoembolisation-based combination therapy as a potential new standard for intermediate-stage hepatocellular carcinoma in the targeted immunotherapy era.BMJ open gastroenterology · 2026Review
- Comment on "Development and validation of the NTAA prognostic model for BCLC stage B hepatocellular carcinoma undergoing transarterial chemoembolization: a retrospective multicenter cohort study".International journal of surgery (London, England) · 2026Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveOur aim was to establish a valid new prognostic predictive tool for assessing the outcomes after TACE treatment in hepatocellular carcinoma (HCC) patients with Child-Pugh A at Barcelona clinical liver cancer stage B (BCLC B) undergoing transarterial chemoembolization (TACE). METHODS AND MATERIALS: We retrospectively analyzed 2529 HBV-related BCLC B HCC patients with Child-Pugh grade A who received initial TACE treatment, with 1075 in the primary cohort, 1076 in the internal validation cohort, and the remaining 378 in the multicenter external validation cohort. The NTAA prognostic model was constructed by Cox proportional hazards regression. The prognostic prediction performance of the NTAA prognostic model with AJCC staging and other criterion were compared by the time-dependent ROC and C-index. In addition, we included 305 patients of non-HBV-related BCLC stage B HCC who received TACE treatment in our center to further validate the predictive performance of the NTAA model.
resultsTumor size, tumor number, alpha-fetoprotein level, and albumin-bilirubin grade were found to be independent factors affecting overall survival (OS) after TACE in these patients. The NTAA prognostic model established accordingly divided patients into low-risk, intermediate-risk, and high-risk groups, with a median survival of 68.1, 35.7, and 15.4 months, respectively. The time-dependent ROC and C-index showed that the NTAA prognostic model was better than other existing criterion and AJCC staging in predicting OS, especially in predicting early OS rates. Furthermore, the NTAA criteria were validated in the internal validation cohort, multicenter external validation cohort, and non-HBV-related HCC cohort.
conclusionThe proposed NTAA prognostic prediction model provides more accurate prognosis prediction of BCLC B HCC patients with Child-Pugh A who received TACE. The implementation of this model promises to improve the clinical decision-making process and provide more personalized treatment options for patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.